Help prevent liver cancer from returning after treatment
Part of Cancer, Digestive system clinical trials.
This study tests whether a Chinese herbal medicine called Biejia-Ruangan Compound can help people with early-stage liver cancer who have already had successful treatment (surgery or ablation) live longer and keep the cancer from coming back. It is for people who also have chronic hepatitis B.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have chronic hepatitis B with liver fibrosis or cirrhosis.
- You have been diagnosed with early-stage liver cancer (CNLC stage Ia to IIa).
- You have already completed curative treatment (surgery or ablation) within the past 8 to 12 weeks, and no cancer remains.
- Your liver function is good enough (Child-Pugh score A or B).
- You have not had other anti-tumor treatments (like chemotherapy or immunotherapy) before your liver surgery or ablation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding a Chinese herbal medicine called Fufang Biejiaruangan to standard antiviral therapy can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis. If you are at higher risk for liver cancer, this combination might help prevent it.
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
This study looks at whether giving antiviral medicine after liver cancer treatment helps prevent the cancer from coming back and improves overall outcomes. It is for people with hepatitis B who have had their liver cancer removed or destroyed with a procedure.
This trial tests a medication (pegylated interferon alfa-2b) for people with hepatitis B-related liver cancer that has been completely removed by surgery or ablation. The goal is to see if this treatment can help prevent the cancer from coming back.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.